Cinctive Capital Management’s Charles River Laboratories CRL Stock Holding History

Cinctive Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-42,944	Closed	-$6.52M	–	419
2025 Q2	$6.52M	Buy	42,944 +40,956	+2,060%	+$5.46M	0.34%	99
2025 Q1	$299K	Sell	1,988 -10,264	-84%	-$1.72M	0.02%	286
2024 Q4	$2.26M	Buy	+12,252	New	+$2.36M	0.12%	206
2024 Q2	–	Sell	-21,329	Closed	-$5.78M	–	417
2024 Q1	$5.78M	Buy	+21,329	New	+$5.09M	0.27%	117
2023 Q2	–	Sell	-25,844	Closed	-$5.22M	–	386
2023 Q1	$5.22M	Buy	25,844 +13,427	+108%	+$3.04M	0.17%	193
2022 Q4	$2.71M	Buy	+12,417	New	+$2.71M	0.13%	227

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cinctive Capital Management's CRL Position: Q3 2025 in Review

Cinctive Capital Management sold out of Charles River Laboratories (CRL) in Q3 2025, closing a stake of 42,944 shares — an estimated $6.52M sold.

Cinctive Capital Management first reported a position in CRL in Q4 2022 and held it in 6 quarters. The position peaked at $6.52M in Q2 2025. 556 funds tracked by Wall St. Rank hold CRL as of Q3 2025.

Cinctive Capital Management reported no remaining Charles River Laboratories position as of Q3 2025 after selling out during the quarter.
Cinctive Capital Management sold 42,944 Charles River Laboratories shares in Q3 2025, an estimated $6.52M.
Cinctive Capital Management first reported a position in Charles River Laboratories in Q4 2022 and held it in 6 quarters.
Cinctive Capital Management's Charles River Laboratories position peaked at $6.52M in Q2 2025.
556 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.

Based on Cinctive Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.